Repros Therapeutics (NASDAQ: RPRX) and Sorrento Tech (NASDAQ:ROKA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Insider and Institutional Ownership
13.6% of Repros Therapeutics shares are held by institutional investors. Comparatively, 48.1% of Sorrento Tech shares are held by institutional investors. 2.5% of Repros Therapeutics shares are held by company insiders. Comparatively, 29.2% of Sorrento Tech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Repros Therapeutics and Sorrento Tech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Repros Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Sorrento Tech has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Repros Therapeutics and Sorrento Tech, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Repros Therapeutics currently has a consensus price target of $0.39, suggesting a potential downside of 41.79%. Given Repros Therapeutics’ higher possible upside, equities research analysts plainly believe Repros Therapeutics is more favorable than Sorrento Tech.
Valuation & Earnings
This table compares Repros Therapeutics and Sorrento Tech’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Repros Therapeutics||$50,000.00||530.10||-$17.27 million||($0.50)||-1.34|
|Sorrento Tech||$7.24 million||0.45||-$30.78 million||($8.79)||-0.07|
Repros Therapeutics has higher earnings, but lower revenue than Sorrento Tech. Repros Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Tech, indicating that it is currently the more affordable of the two stocks.
Sorrento Tech beats Repros Therapeutics on 8 of the 12 factors compared between the two stocks.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.
Sorrento Tech Company Profile
Sorrento Tech, Inc., formerly Roka Bioscience, Inc., is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.